Edition:
United Kingdom

Koninklijke DSM NV (DSMN.AS)

DSMN.AS on Amsterdam Stock Exchange

81.16EUR
10:52am BST
Change (% chg)

€0.80 (+1.00%)
Prev Close
€80.36
Open
€80.56
Day's High
€81.92
Day's Low
€79.46
Volume
387,779
Avg. Vol
691,297
52-wk High
€93.04
52-wk Low
€71.32

Latest Key Developments (Source: Significant Developments)

Silfab Solar And DSM Announce Partnership For Production Of High-Power Back-Contact Pv Solar Modules
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Koninklijke DSM NV ::STRATEGIC ALLIANCE BETWEEN SILFAB SOLAR AND DSM TO MASS PRODUCE HIGH-POWER BACK-CONTACT PV SOLAR MODULES.  Full Article

DSM Intends To Repurchase In Total 1,100,000 Ordinary Shares
Monday, 13 Aug 2018 

Aug 13 (Reuters) - KONINKLIJKE DSM NV ::STARTING 13 AUGUST 2018, IT INTENDS TO REPURCHASE IN TOTAL 1,100,000 ORDINARY SHARES.500,000 ORDINARY SHARES TO COVER COMMITMENTS UNDER SHARE-BASED COMPENSATION PLANS.THE REPURCHASE PRICE WILL BE BASED ON THE DAILY VWAP (VOLUME WEIGHTED AVERAGE PRICE).600,000 ORDINARY SHARES TO COVER COMMITMENTS FOR STOCK DIVIDEND.BASED ON CLOSING PRICE OF DSM SHARE ON EURONEXT AMSTERDAM ON 10 AUGUST 2018 THIS WOULD BE EQUIVALENT TO APPROXIMATELY EUR 99 MILLION.VOLUMES TO BE REPURCHASED WILL BE ON AVERAGE 5% OF THE DAILY TRADING VOLUME ON THE OPEN MARKET, WITHIN A BANDWIDTH OF 2-8% PER DAY.TOTAL SHARE REPURCHASE PROGRAM IS ANTICIPATED TO CONTINUE INTO Q4 2018.  Full Article

DSM H1 Sales Up At EUR 4.79 Billion
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Koninklijke DSM NV ::H1 SALES EUR 4.79 BILLION VERSUS EUR 4.32 BILLION YEAR AGO.SAYS INTERIM DIVIDEND OF €0.77, REFLECTING THE PROPOSED DIVIDEND INCREASE OF ABOUT 25% FOR 2018.H1 TOTAL GROUP ADJUSTED EBITDA EUR 1.05 BILLION VERSUS EUR 721.0 MILLION (REPORTED) YEAR AGO.CONFIRMS ITS FULL YEAR OUTLOOK 2018.H1 CASH FROM OPERATING ACTIVITIES €503M UP 53%.SAYS H1 NET PROFIT UP 103% TO EUR 633 MLN.  Full Article

DSM Becomes Largest Shareholder in Mixfit Inc. to Enter B2C Personalized Nutrition
Monday, 2 Jul 2018 

July 2 (Reuters) - Koninklijke DSM NV ::IS NOW MIXFIT'S LARGEST SHAREHOLDER WITH APPROXIMATELY 50% OF SHARES.FINANCIAL DETAILS WILL NOT BE DISCLOSED AT THIS TIME.  Full Article

DSM announces sale Of DSM Sinochem Pharmaceuticals to Bain Capital
Friday, 29 Jun 2018 

June 29 (Reuters) - Koninklijke DSM NV ::DSM INFORMS MARKET ON THE ANNOUNCED SALE OF DSM SINOCHEM PHARMACEUTICALS TO BAIN CAPITAL.DSM AND SINOCHEM GROUP EACH OWN 50% OF SHARES OF DSP.DSM - WILL RECEIVE ABOUT EUR 250 MILLION FOR ITS EQUITY STAKE, EXCLUDING AN EARN-OUT (ESTIMATED AT AROUND EUR 50M) AND TRANSACTION COSTS.DSM - EXPECTS TO RECEIVE APPROXIMATELY EUR 275 MILLION IN CASH FOLLOWING CLOSING, INCLUDING REPAYMENT OF DEBT AND AFTER TRANSACTION COSTS.  Full Article

DSM has around 3 bln euros available for acquisitions - CFO
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Koninklijke DSM NV ::DSM WILL LOOK TO EXPAND NUTRITIONAL PORTFOLIO INTO WHOLE FOOD AND BEVERAGE AREA - CEO.DSM: NO SET TIMEFRAME FOR ACQUISITIONS - CEO.DSM HAS AROUND 3 BILLION EUROS AVAILABLE FOR ACQUISITIONS - CFO.  Full Article

DSM Sees In 2019-21 High Single-Digit Annual Percentage Increase In Adj. EBITDA
Wednesday, 20 Jun 2018 

June 20 (Reuters) - KONINKLIJKE DSM NV ::IN 2019-21 (NOT 2015-18) CO WILL POSITION ITSELF TOWARDS A NUTRITION, HEALTH AND SUSTAINABLE LIVING COMPANY, PURSUING ENHANCED ORGANIC GROWTH, WITH A PURPOSE-LED COHERENT SET OF BUSINESS ACTIVITIES.IN 2019-21(NOT 2015-18) VALUE-CREATING ACQUISITIONS PREDOMINANTLY IN NUTRITION.STRATEGY UPDATE.2018 OUTLOOK, AS ISSUED ON 8 MAY, RECONFIRMED.TWO FINANCIAL TARGETS HAVE BEEN SET FOR PERIOD 2019-2021: HIGH SINGLE-DIGIT ANNUAL PERCENTAGE INCREASE IN ADJUSTED EBITDA.PERIOD 2019-2021: ABOUT 10% AVERAGE ANNUAL INCREASE IN ADJUSTED NET OPERATING CASH FLOW.AIMS FOR HIGH SINGLE-DIGIT ANNUAL PERCENTAGE INCREASE IN ADJUSTED EBITDA IN 2019-2021.AIMS FOR ABOUT 10% AVERAGE ANNUAL INCREASE IN ADJUSTED NET OPERATING CASH FLOW IN 2019-2021.NEW ADJUSTED EBITDA MARGIN AMBITIONS BY 2021:* NUTRITION OVER 20%.NEW ADJUSTED EBITDA MARGIN AMBITIONS BY 2021: MATERIALS 18-20%.WILL PROPOSE DIVIDEND INCREASE OF ABOUT 25% TO €2.30 PER ORDINARY SHARE OVER 2018.25% DIVIDEND INCREASE OVER 2018, WITH FUTURE DIVIDEND GROWTH ALIGNED WITH LONG-TERM EARNINGS GROWTH.PERFORMANCE EXPECTED TO RESULT IN FURTHER DIVIDEND GROWTH, WHICH COULD LEAD TO AN EXPECTED AVERAGE PAYOUT OF 40-50% OF ADJUSTED (UNDERLYING) EARNINGS.FOCUS ON INVESTMENT AND CASH GENERATION TO IMPROVE RETURNS AND ACCELERATE GROWTH IN OPERATING CASH FLOW OF ABOUT 10% ANNUALLY.  Full Article

DSM Q1 Sales Up At 2.44 Billion Euros
Tuesday, 8 May 2018 

May 8 (Reuters) - KONINKLIJKE DSM NV ::Q1 CONTINUED STRONG ORGANIC SALES GROWTH IN UNDERLYING BUSINESS ESTIMATED AT 11% .Q1 TOTAL ADJUSTED EBITDA UP 56% AND NET PROFIT UP 122% TO €331M.DSM CONFIRMS ITS INCREASED FULL YEAR OUTLOOK 2018, AS ANNOUNCED ON 12 APRIL 2018.AT END Q1 CASH FROM OPERATING ACTIVITIES UP 58%, AMOUNTING TO €310M.Q1 SALES EUR 2.44 BILLION VERSUS EUR 2.16 BILLION YEAR AGO.  Full Article

DSM Q1 Adjusted EBITDA Up At 535 Million Euros
Thursday, 12 Apr 2018 

April 12 (Reuters) - KONINKLIJKE DSM NV ::CONTINUED STRONG ORGANIC SALES GROWTH IN UNDERLYING BUSINESS ESTIMATED AT 11PCT IN Q1.Q1 ADJUSTED EBITDA EUR 535 MILLION VERSUS EUR 345 MILLION YEAR AGO.RAISES ITS FULL YEAR OUTLOOK 2018 AND NOW EXPECTS AN ADJUSTED EBITDA GROWTH TOWARDS 25%.Q1 UNDERLYING BUSINESS IS ESTIMATED TO BE 3% AND ADJUSTED EBITDA GROWTH 7%.Q1 REVENUE EUR 2.44 BILLION VERSUS EUR 2.16 BILLION YEAR AGO.INCLUDING NEGATIVE FOREIGN EXCHANGE EFFECTS, ADJUSTED EBITDA EXPECTED UP 11%, ADJUSTED EBITDA MARGIN C. 17%.  Full Article

DSM Acquires Biocare Copenhagen
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Koninklijke Dsm Nv ::DSM ACQUIRES BIOCARE COPENHAGEN TO EXPAND GUT HEALTH INGREDIENTS PORTFOLIO WITH PROBIOTICS.FINANCIAL DETAILS WILL NOT BE DISCLOSED AT THIS TIME.  Full Article

UPDATE 1-DSM's Q2 core profit surges 35 pct on vitamin boost; confirms outlook

AMSTERDAM, Aug 1 Dutch speciality chemicals company DSM on Wednesday said second-quarter core profit surged 35 percent to 508 million euros ($593.2 million), boosted by exceptionally high vitamin prices and cost cuts.